Payment overview · 2025
General Payments
$44,401.42
93 reported records · 26 companies
Healthcare provider profile · identity verified
Billy John Kim, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · MOUNT JULIET, TN · NPI 1942404728
Verified facts
What the public records show
CMS Open Payments records show Billy John Kim, MD received $44,401.42 in general payments during 2025 across 93 reported records.
AngioDynamics, Inc. accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $20,354.17 | 45.8% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$12,994.86 | 29.3% | 25 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $5,876.47 | 13.2% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,128.70 | 4.8% | 7 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $1,012.09 | 2.3% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $479.17 | 1.1% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $430.74 | 1.0% | 6 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $278.38 | 0.6% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $192.54 | 0.4% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $64.83 | 0.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.95 | 0.1% | 3 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $61.98 | 0.1% | 3 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $58.63 | 0.1% | 3 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $52.00 | 0.1% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $49.37 | 0.1% | 1 | 2025 |
| Innovation Technologies Inc | Unresolved — no canonical attribution shown | $48.47 | 0.1% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $46.77 | 0.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $46.11 | 0.1% | 2 | 2025 |
| LifeNet Health | Unresolved — no canonical attribution shown | $31.56 | 0.1% | 2 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $31.06 | 0.1% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $21.69 | 0.1% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $19.46 | 0.0% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $15.52 | 0.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $15.31 | 0.0% | 1 | 2025 |
| Artivion, Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.0% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $14.06 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $20,354.17 | 3 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,475.00 | 2 |
| Consulting Fee | $6,700.00 | 5 |
| Food and Beverage | $4,430.58 | 75 |
| Travel and Lodging | $941.67 | 7 |
| Compensation for serving as faculty or as a speaker for a medical education program | $500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $20,354.17 | 3 | 2025 |
Source payment records
|
|||||
| ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY Normalized: anteralign spinal system with titan nanolock surface technology |
Device | Medtronic, Inc. | $8,815.99 | 13 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $5,876.47 | 13 | 2025 |
Source payment records
|
|||||
| CD HORIZON SPINAL SYSTEM Normalized: cd horizon spinal system |
Device | Medtronic, Inc. | $3,993.78 | 10 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $2,006.52 | 6 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $788.84 | 2 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $479.17 | 4 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $386.63 | 3 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $240.79 | 1 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $223.25 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $192.54 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $185.09 | 2 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $122.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.95 | 3 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $58.63 | 3 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $52.00 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $49.37 | 1 | 2025 |
Source payment records
|
|||||
| IRRISEPT Normalized: irrisept |
Device | Innovation Technologies Inc | $48.47 | 2 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $46.77 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $37.59 | 1 | 2025 |
Source payment records
|
|||||
| TheraGenesis Wound Matrix Normalized: theragenesis wound matrix |
Device | LifeNet Health | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $31.06 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $31.06 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $21.54 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.INSTILL Normalized: v a c instill |
Device | Solventum Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Vascular Normalized: vascular |
Device | Artivion, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 164 | 63 |
| Xarelto | Rivaroxaban | 46 | 14 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $44,401.42 · 93 records | AngioDynamics, Inc. | ACTIV.A.C., AFX2 Bifurcated Endograft System, ANGIO-SEAL, ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY, ARTIX MT, Altius, Alto Abdominal Stent Graft System, Auryon Laser System 100-120 Vac, CD HORIZON SPINAL SYSTEM, CT THROMBECTOMY SYSTEM KIT, ENDURANT IIS, ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent, ESPRIT, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GORE TAG Thoracic Branch Endoprosthesis, GRAFIX PL, IRRISEPT, Nimbl, OPTOWIRE, PERCLOSE PROSTYLE, PREVENA, Penumbra System, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, RotarexS 6 F x 135 cm, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TREO ABDOMINAL STENT-GRAFT SYSTEM, TheraGenesis Wound Matrix, V.A.C.INSTILL, Vascular, WaveWriter Alpha Prime 16, Wegovy, ZENITH SPIRAL-Z, ZILVER PTX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error